603108 润达医疗
2024/06 - 中期
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入4,135,268-8.54%9,147,37310,494,4198,860,1087,069,156
减:营业总成本3,899,504-7.55%8,651,9939,643,2848,160,2466,523,570
    其中:营业成本3,014,618-8.67%6,715,7457,557,0676,468,0945,157,435
               财务费用158,7631.30%316,682323,591291,634241,605
               资产减值损失(131)-30.52%(34,500)(40,772)(7,299)(737)
公允价值变动收益----------(3,589)
投资收益70,4253.42%231,999137,048137,876139,857
    其中:对联营企业和合营企业的投资收益70,2773.41%139,609138,057133,628133,634
营业利润232,218-31.78%646,803816,373777,798643,762
利润总额236,822-31.94%655,555819,651780,456635,836
减:所得税费用84,546-2.39%212,920164,541182,255132,005
净利润152,276-41.73%442,636655,110598,201503,830
减:非控股权益60,970-29.39%169,339237,364217,972173,849
股东净利润91,306-47.82%273,296417,746380,229329,981

市场价值指针
每股收益 (元) *0.150-50.00%0.4700.7200.6600.570
每股派息 (元) *----0.1000.150--0.114
每股净资产 (元) *7.1367.08%7.0606.5195.7855.337
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容